CRISPR Therapeutics AG
CRISPR Therapeutics AG (CRSP) Shares Outstanding — Overview
Basic and diluted weighted average shares, YoY change, float context, and historical trend from SEC filings and FMP.
CRSP · shares outstanding · updated Jun 8, 2026
Key metrics
as of Dec 31, 2025Shares Outstanding Growth Rate
CAGR · weighted avg basic sharesNegative CAGR typically indicates share buyback or retirement activity. Interpret alongside Splits and Financials tabs. Splits / Financials
Shares outstanding history
Annual shares outstanding by year
Healthcare sector shares outstanding comparison
Shares Outstanding for similar companies or competitors in the Healthcare sector.
MRK
JNJ
ABBV
AZN
UNH
LLYCRSP/company-screener · per-peer /income-statement · cache 86400s
Understanding Shares Outstanding
Basic · Diluted · FloatWhat Are Shares Outstanding? (Basic)
CRISPR Therapeutics AG (CRSP) shares outstanding is the total number of issued shares held by shareholders — the basis for Basic EPS and market capitalization. As of December 31, 2025, CRISPR Therapeutics AG reports 89.9M basic shares outstanding (weighted average).
Basic vs. Diluted Shares Outstanding
CRISPR Therapeutics AG's basic shares outstanding (89.9M) represents currently issued shares. Diluted shares outstanding (89.9M) also includes potential shares from stock options, RSUs, and convertibles. Dilution spread: +0.00%.
Shares Outstanding vs. Float (Free Float)
CRISPR Therapeutics AG's float is 96.0M (99.6% of total shares outstanding) — shares freely available for public trading, excluding insider-held and restricted shares.
ⓘ Float data from /shares-float reflects the most recent SEC filing period-end. The weighted average shares (from /income-statement) may differ — this is a normal reporting window difference, not a data error.
FMP /income-statement · /shares-float · SEC EDGAR · USD
About shares outstanding & methodology
CRISPR Therapeutics AG (CRSP) shares outstanding history from 2014 to 2025. Shares outstanding can be defined as the total number of shares held by all shareholders — including institutional investors, retail investors, and company insiders — assuming conversion of all convertible debt, securities, warrants, and options. This metric excludes the company's treasury shares.
CRISPR Therapeutics AG shares outstanding for the fiscal year ending December 31, 2025 were 89.9M, a 6.60% increase year-over-year. CRISPR Therapeutics AG FY 2025 shares outstanding were 89.9M, a +6.60% increase from FY 2024.
CRISPR Therapeutics AG is a leading company operating in the Healthcare sector. The company's share count trajectory — with a 10-year CAGR of +11.9% — is a key signal for investors evaluating capital return policy, EPS accretion, and long-term shareholder value creation.
Frequently asked questions
CRSP shares outstanding · 4 questionsAs of December 31, 2025, CRISPR Therapeutics AG (CRSP) has approximately 89.9M basic shares outstanding and 89.9M diluted shares outstanding. This represents a +6.60% year-over-year increase from FY 2024 (84.4M). The increase may reflect equity compensation issuances or secondary offerings.
▸ Data: FMP /income-statement · /shares-float · SEC EDGAR · weighted average basis · CRISPR Therapeutics AG SEC 10-K & 10-Q filings · US GAAP · Last updated: 2026-06-08